Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Recently, the weight loss drug introduced by Eli Lilly, Mounjaro, has been launched in India sparking a debate among health experts ...

Nvidia’s momentum has been weighed down by cooling AI hype and broader market instability. Despite reporting blockbuster Q4 ...

Eli Lilly has raised its revenue guidance for 2024 ... Tirzepatide-based medicines Mounjaro for diabetes and Zepbound for obesity have led the charge, contributing $3.1 billion and $1.2 billion ...